Policy

Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices…

This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the m…

A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newslet…

Following a series of “most favored nation” pricing deals with 17 large pharma companies, the Trump administra…

This page displays an interactive map of the current status of state decisions on the Affordable Care Act's Me…

This brief reviews the case now before the Supreme Court, Louisiana v. FDA, and provides an overview of the ot…